Benzene-Ring P2X4 Antagonist Scaffold for Selective Cough Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs targeting the P2X4 receptor for treating cough and other respiratory conditions lack effective compounds with high antagonistic activity, selectivity, and metabolic stability.
Innovation Solution
Development of a compound containing a benzene ring with specific functional groups that act as a P2X4 antagonist, offering high antagonistic activity, good selectivity, and low toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing P2X4 antagonist structures are used, then the structural simplicity is maintained, but the antagonistic activity and selectivity are insufficient
Solution Approach 1:
The compound structure is divided into multiple functional modules: a benzene ring core (providing structural scaffold), specific substituent groups (providing biological activity), and linker regions (providing spatial arrangement). This segmentation allows optimization of each module's function while maintaining overall structural coherence, thereby achieving high antagonistic activity without excessive complexity.
Solution Approach 2:
Specific regions of the molecule are optimized with particular functional groups and substituents at defined positions to enhance binding affinity and selectivity for the P2X4 receptor. The local chemical environment is tailored to match the receptor's binding pocket characteristics, improving antagonistic activity while keeping the overall structure manageable.
2Reliability
If high antagonistic activity is achieved through complex structures, then the efficacy is improved, but the metabolic stability and toxicity profile worsen
Solution Approach 1:
The chemical parameters of the compound are optimized by adjusting substituent types, positions, and electronic properties to achieve the desired balance. By changing parameters such as hydrophobicity, molecular weight, and functional group composition, the compound achieves high antagonistic activity while maintaining metabolic stability and acceptable toxicity profile.
3Loss of time
If existing compounds are used for P2X4 targeting, then the development time is reduced, but the efficacy for cough treatment is insufficient
Solution Approach 1:
The compound design incorporates preliminary optimization of key structural features known to be important for P2X4 binding, based on prior structural activity relationship studies. This preliminary action allows the compound to achieve high efficacy from the outset, reducing the need for extensive later optimization while still providing superior cough treatment efficacy compared to existing compounds.
Data Source
AI summary
A compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof are provided. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.